Galantamine Extended-Release Capsules

**Type of Posting**  Revision Bulletin  
**Posting Date**  27–May–2016  
**Official Date**  01–Jun–2016  
**Expert Committee**  Chemical Medicines Monographs 4  
**Reason for Revision**  Compliance

In accordance with the Rules and Procedures of the 2015-2020 Council of Experts, the Chemical Medicines Monographs Expert Committee has revised the Galantamine Extended-Release Capsules monograph. The purpose for the revision is to add two dissolution tests for drug products approved by the FDA.

- *Dissolution Test 4* was validated using an Xterra RP 18 brand of L1 column. The typical retention time for galantamine is about 4 to 5 min.
- *Dissolution Test 5* was validated using a Luna C8(2) brand of L7 column. The typical retention time for galantamine is about 4.5 min.

Additionally, minor editorial changes have been made to update the monograph to current *USP* style.

The Galantamine Extended-Release Capsules Revision Bulletin supersedes the currently official monograph. The Revision Bulletin will be incorporated in *USP 40–NF 35*.

Should you have any questions, please contact Heather Joyce, Ph. D., Senior Scientific Liaisons (301–881–0666 or *hrj@usp.org*).
Galantamine Extended-Release Capsules

DEFINITION
Galantamine Extended-Release Capsules contain galantamine hydrobromide (C17H21NO3·HBr) equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of galantamine (C17H21NO3).

[NOTE—Throughout the following procedures, protect samples, the Reference Standard, and solutions containing them from light by using low-actinic glassware.]

IDENTIFICATION

A. INFRARED ABSORPTION (197K)
Sample: Prepare a potassium bromide dispersion as follows. Remove four beads from within one Capsule. Grind the beads into a fine powder, and combine with potassium bromide.
Standard: Prepare a potassium bromide dispersion using USP Galantamine Hydrobromide RS.
Acceptance criteria: The IR spectra of the Sample and the Standard exhibit similar absorption bands at 2800–2400 cm⁻¹, 1700–1500 cm⁻¹, and 850–750 cm⁻¹.

B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY

Change to read:

PROCEDURE
Buffer: 4.0 g/L of monobasic potassium phosphate in water adjusted with 0.5 N sodium hydroxide TS (88-1-Jun-2016) to a pH of 6.5.
Mobile phase: Acetonitrile and Buffer (10:90)
Standard stock solution: 0.62 mg/mL of USP Galantamine Hydrobromide RS (equivalent to 0.48 mg/mL of galantamine) prepared as follows. Transfer a suitable quantity of USP Galantamine Hydrobromide RS to a suitable flask, and dissolve in 20% of the flask volume of methanol. Dilute with Buffer to volume.
Standard solution: 0.048 mg/mL of galantamine from the Standard stock solution in Buffer
Sample stock solution: Prepare the solution using the appropriate nominal concentration of galantamine stated in Table 1. Transfer the contents of 10 Capsules to a suitable volumetric flask. Add 20% of the final flask volume of methanol, sonicate for 15 min, and stir for 20 min. Add a suitable volume of Buffer such that 80% of the final flask volume is filled, and stir for 90 min. Dilute with Buffer to volume.

Table 1

<table>
<thead>
<tr>
<th>Capsule Strength (mg/Capsule)</th>
<th>Nominal Concentration of Galantamine (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>0.32</td>
</tr>
<tr>
<td>16</td>
<td>0.32</td>
</tr>
<tr>
<td>24</td>
<td>0.48</td>
</tr>
</tbody>
</table>

Sample solution: Nominally 0.048 mg/mL of galantamine prepared as follows from the Sample stock solution. Transfer a suitable volume of the Sample stock solution to an appropriate volumetric flask, and dilute with Buffer to volume. Pass through a suitable filter of 0.45-μm pore size. Discard the first 5 mL, and use the filtrate.

Chromatographic system
(See Chromatography (621), System Suitability.)
Mode: LC
Detector: UV 288 nm
Column: 4.6-mm × 15.0-cm; 5-μm packing L1
Flow rate: 1.2 mL/min
Injection volume: 20 μL

System suitability
Sample: Standard solution
Suitability requirements
Tailing factor: NMT 1.7
Relative standard deviation: NMT 1.0%

Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of the labeled amount of galantamine (C17H21NO3) in the portion of Capsules taken:

Result = \((r_S/r_U) \times (C_S/C_D) \times (M_r1/M_r2) \times 100\)

\(r_S\) = peak response from the Sample solution
\(r_U\) = peak response from the Standard solution
\(C_S\) = concentration of USP Galantamine Hydrobromide RS in the Standard solution (mg/mL)
\(C_D\) = nominal concentration of galantamine in the Sample solution (mg/mL)
\(M_r1\) = molecular weight of galantamine, 287.35
\(M_r2\) = molecular weight of galantamine hydrobromide, 368.27

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

Dissolution (711)
Test 1
Medium: 0.05 M monobasic potassium phosphate, pH 6.5; 900 mL
Apparatus 2: 50 rpm with sinkers
[NOTE—A suitable sinker is catalog number CAPWHT-2S from www.qla-llc.com.]
Times: 1, 4, and 12 h
Buffer: 1 g/L of sodium 1-hexanesulfonate in water. Add 0.5 mL of phosphoric acid per L.
Mobile phase: Acetonitrile and Buffer (20:80)
Standard stock solution: 0.57 mg/mL of USP Galantamine Hydrobromide RS (equivalent to 0.44 mg/mL of galantamine) in Medium
Standard solution: (L/900) mg/mL of galantamine from the Standard stock solution in Medium, where L is the label claim of galantamine in mg/Capsule
Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45-μm pore size.
Chromatographic system
(See Chromatography (621), System Suitability.)
Mode: LC
Detector: UV 280 nm
Column: 4.6-mm × 15.0-cm; 5-μm packing L1
Flow rate: 1 mL/min
Injection volume: 50 μL
Run time: NLT 1.5 times the retention time of galantamine

©2016 The United States Pharmacopeial Convention All Rights Reserved.
2 Galantamine

System suitability
Sample: Standard solution
Suitability requirements
Relative standard deviation: NMT 2.0%
Analysis
Samples: Standard solution and Sample solution
Calculate the concentration (C) of galantamine
\((C_1H_2N_3NO_2)\) in the sample withdrawn from the vessel at each time point (t):

\[ \text{Result}_1 = (r_0/r_1) \times C_1 \times (M_1/M_2) \]

\( r_0 \) = peak response from the Standard solution
\( r_1 \) = peak response from the Sample solution
\( C_1 \) = concentration of USP Galantamine Hydrobromide RS in the Standard solution
\( M_1 \) = molecular weight of galantamine, 287.35
\( M_2 \) = molecular weight of galantamine hydrobromide, 368.27

Calculate the percentage of the labeled amount of galantamine \((C_1H_2N_3NO_2)\) dissolved at each time point (h):

\[ \text{Result}_2 = (C_2 \times (V - V_2)) \times (1/L) \times 100 \]

\( C_2 \) = concentration of galantamine in the portion of sample withdrawn at time point i (mg/mL)
\( V \) = volume of Medium, 900 mL
\( L \) = label claim (mg/Capsule)
\( V_2 \) = volume of the Sample solution withdrawn at each time point (mL)

Tolerances: See Table 2.

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Time (h)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>20-40</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>40-65</td>
</tr>
<tr>
<td>3</td>
<td>12</td>
<td>NLT 75</td>
</tr>
</tbody>
</table>

The percentage of the labeled amount of galantamine \((C_1H_2N_3NO_2)\) dissolved at the times specified conforms to Dissolution (711), Acceptance Table 2.

Test 2: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 2.
Medium: 0.05 M monobasic potassium phosphate, pH 6.5; 900 mL
Apparatus 2: 50 rpm
Times: 1, 4, and 12 h
Solution A: *Transfer 0.5 mL of phosphoric acid to a 100-mL volumetric flask containing 50% of the flask volume of water. Dilute with water to volume.* (8/1/16)
Mobile phase: Acetonitrile and Solution A (7:93)

Standard stock solution: 0.23 mg/mL of USP Galantamine Hydrobromide RS (equivalent to 0.18 mg/mL of galantamine) in Medium
Standard solution: \( (L/900) \) mg/mL of galantamine from the Standard stock solution in Medium, where L is the label claim of galantamine, in mg/Capsule

Sample solution: Pass a portion of the solution under test through a suitable filter.

Chromatographic system
(See Chromatography (621), System Suitability.)
Mode: LC
Detector: UV 230 nm
Column: 3.0-mm \( \times 15.0 \) cm; 5-\( \mu \)m packing L1
Column temperature: 35°
Flow rate: 0.7 mL/min
Injection volume: 10 µL
Run time: NLT 1.6 times the retention time of galantamine

System suitability
Sample: Standard solution
Suitability requirements
Relative standard deviation: NMT 2.0%
Analysis
Samples: Standard solution and Sample solution
Calculate the concentration (C) of galantamine
\((C_1H_2N_3NO_2)\) in the sample withdrawn from the vessel at each time point (t):

\[ \text{Result}_1 = (r_0/r_1) \times C_3 \times (M_1/M_2) \]

\( r_0 \) = peak response from the Standard solution
\( r_1 \) = peak response from the Sample solution
\( C_3 \) = concentration of USP Galantamine Hydrobromide RS in the Standard solution
\( M_1 \) = molecular weight of galantamine, 287.35
\( M_2 \) = molecular weight of galantamine hydrobromide, 368.27

Calculate the percentage of the labeled amount of galantamine \((C_1H_2N_3NO_2)\) dissolved at each time point (h):

\[ \text{Result}_2 = (C_2 \times (V - V_2)) \times (1/L) \times 100 \]

\( C_2 \) = concentration of galantamine in the portion of sample withdrawn at time point i (mg/mL)
\( V \) = volume of Medium, 900 mL
\( L \) = label claim (mg/Capsule)
\( V_2 \) = volume of the Sample solution withdrawn at each time point (mL)

Tolerances: See Table 3.

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Time (h)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>22-38</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>50-70</td>
</tr>
<tr>
<td>3</td>
<td>12</td>
<td>NLT 80</td>
</tr>
</tbody>
</table>

The percentage of the labeled amount of galantamine \((C_1H_2N_3NO_2)\) dissolved at the times specified conforms to Dissolution (711), Acceptance Table 2.

Test 3: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 3.
Medium: pH 6.5 phosphate buffer (6.8 g/L of monobasic potassium phosphate and 0.56 g/L of sodium hydroxide adjusted, if necessary, with phosphoric acid of 10 N sodium hydroxide TS) to a pH of 6.5; 900 mL.
**Apparatus 2:** 50 rpm, with stainless steel wire helix

**Times:** 1, 2, 4, and 12 h

**Buffer:** To each L of 6.8 g/L potassium phosphate in water add 3.0 mL of triethylamine, and adjust the resulting solution with phosphoric acid to a pH of 2.5. Pass through a suitable membrane filter of 0.45-µm pore size, and use the filtrate.

**Mobile phase:** Acetonitrile and Buffer (8:92)

**Standard stock solution:** 0.23 mg/mL of USP Galantamine Hydrobromide RS (equivalent to 0.18 mg/mL of galantamine) in Medium

**Standard solution:** (L/900) mg/mL of galantamine from the Standard stock solution in Medium, where L is the label claim of galantamine, in mg/Capsule

**Sample solution:** Pass a portion of the solution under test through a suitable filter. Replace the portion of solution withdrawn with an equal volume of Medium.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

**Mode:** LC

**Detector:** UV 230 nm

**Column:** 4.6-mm × 15.0-cm; 5-µm packing L1

**Flow rate:** 1.5 mL/min

**Injection volume:** 50 µL

**Run time:** NLT 2 times the retention time of galantamine

**System suitability**

**Sample:** Standard solution

**Suitability requirements**

**Tailing factor:** NMT 2

**Relative standard deviation:** NMT 3.0%

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the concentration (Ci) of galantamine (C17H21NO3) in the sample withdrawn from the vessel at each time point (i):

\[
\text{Result}_i = \left( \frac{r_U}{r_S} \right) \times C_i \times \left( \frac{M_i}{M_S} \right)
\]

\[
r_U = \text{peak response from the Sample solution}
\]

\[
r_S = \text{peak response from the Standard solution}
\]

\[
C_i = \text{concentration of USP Galantamine Hydrobromide RS in the Standard solution (mg/mL)}
\]

\[
M_i = \text{molecular weight of galantamine, 287.35}
\]

\[
M_S = \text{molecular weight of galantamine hydrobromide, 368.27}
\]

Calculate the percentage of the labeled amount of galantamine (C17H21NO3) dissolved at each time point (i):

\[
\text{Result}_i = C_i \times V \times (1/L) \times 100
\]

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>18-43</td>
</tr>
<tr>
<td>2</td>
<td>30-50</td>
</tr>
<tr>
<td>4</td>
<td>NLT 80</td>
</tr>
</tbody>
</table>

**Tolerances:** See Table 4.

**Test 4:** If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 4.

**Medium:** pH 6.5 phosphate buffer (6.8 g/L of monobasic potassium phosphate in water adjusted, if necessary, with 5 N sodium hydroxide TS to a pH of 6.5) 900 mL

**Apparatus 2:** 50 rpm, with sinkers

**Times:** 1, 4, and 12 h

**Buffer:** 6.8 g/L of monobasic potassium phosphate adjusted, if necessary, with 5 N sodium hydroxide TS to a pH of 7.5

**Mobile phase:** Acetonitrile and Buffer (15:85)

**Standard stock solution:** 0.11 mg/mL of USP Galantamine Hydrobromide RS (equivalent to 0.09 mg/mL of galantamine) in Medium

**Standard solution:** (L/900) mg/mL of galantamine from the Standard stock solution in Medium, where L is the label claim of galantamine, in mg/Capsule

**Sample solution:** Pass a portion of the solution under test through a suitable filter.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

**Mode:** LC

**Detector:** UV 230 nm

**Column:** 4.6-mm × 15.0-cm; 5-µm packing L1

**Column temperature:** 30°

**Flow rate:** 1.4 mL/min

**Injection volume:** 100 µL

**Run time:** NLT 1.5 times the retention time of galantamine

**System suitability**

**Sample:** Standard solution

**Suitability requirements**

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the concentration (Ci) of galantamine (C17H21NO3) in the sample withdrawn from the vessel at each time point (i):

\[
\text{Result}_i = \left( \frac{r_U}{r_S} \right) \times C_i \times \left( \frac{M_i}{M_S} \right)
\]

\[
r_U = \text{peak response from the Sample solution}
\]

\[
r_S = \text{peak response from the Standard solution}
\]

\[
C_S = \text{concentration of USP Galantamine Hydrobromide RS in the Standard solution (mg/mL)}
\]

\[
M_i = \text{molecular weight of galantamine, 287.35}
\]

\[
M_S = \text{molecular weight of galantamine hydrobromide, 368.27}
\]
Galantamine

Test 5: Official June 1, 2016

Standard solution: 1, 4, and 12 h forms to times: Dissolution Test 5 indicating that it meets USP 2 4 45±65 50 rpm with sinkers (C17H21NO3) dissolved at the times specified conforms to Dissolution (711), Acceptance Table 2.

Apparatus 2: 50 rpm with sinkers

Times: 1, 4, and 12 h

Buffer: To each L of water add 7 mL of triethylamine. Jun-2016)

Mobile phase: Methanol and Buffer (25:75), adjusted with phosphoric acid or a solution of triethylamine requirements

Medium: pH 6.5 phosphate buffer (6.8 g/L of monobasic potassium phosphate, 3.0 g/L of dibasic potassium phosphate· (RB 1-Jun-2016) in water

Standard solution: 0.025 mg/mL of USP Galantamine Hydrobromide RS (equivalent to 0.02 of galantamine) in Medium

Sample solution: Pass a portion of the solution under test through a suitable filter.

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 280 nm

Column: 4.6-mm × 15.0-cm; 5-µm packing L7

Flow rate: 1 mL/min

Injection volume: 20 µL

Run time: NLT 1.5 times the retention time of galantamine

System suitability

Sample: Standard solution

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: Standard solution and Sample solution

Calculate the concentration (Ci) of galantamine (C17H21NO3) in the sample withdrawn from the vessel at each time point (i):

\[ \text{Result}_i = C_i \times \frac{V_i}{L_i} \times 100 \]

\[ \text{Result}_2 = \left( \frac{C_i \times (V - V_i)}{L_i} \right) \times 100 \]

\[ \text{Result}_3 = \left( \frac{C_i \times (V - 2 \times V_i)}{L_i} \right) \times 100 \]

\[ \frac{C_i}{C_i} = \text{concentration of galantamine in the portion of sample withdrawn at time point } i \text{ (mg/mL)} \]

\[ V = \text{volume of Medium, 900 mL} \]

\[ L = \text{label claim (mg/Capsule)} \]

\[ V_i = \text{volume of the Sample solution withdrawn at each time point (mL)} \]

Tolerances: See Table 5.

Table 5

<table>
<thead>
<tr>
<th>Time Point (i)</th>
<th>Time (h)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>NMT 40</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>45-70</td>
</tr>
<tr>
<td>3</td>
<td>12</td>
<td>NLT 75</td>
</tr>
</tbody>
</table>

The percentage of the labeled amount of galantamine (C17H21NO3) dissolved at the times specified conforms to Dissolution (711), Acceptance Table 2.

Test 5: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 5.

Medium: pH 6.5 phosphate buffer (6.8 g/L of monobasic potassium phosphate adjusted, if necessary, with 0.2 N sodium hydroxide TS to a pH of 6.5); 900 mL

Apparatus 2: 50 rpm with sinkers

Buffer: To each L of water add 7 mL of triethylamine.

Mobile phase: Methanol and Buffer (25:75), adjusted with phosphoric acid or a solution of triethylamine and water (5:95) to a pH of 6.5

Standard solution: 0.025 mg/mL of USP Galantamine Hydrobromide RS (equivalent to 0.02 of galantamine) in Medium

Sample solution: Pass a portion of the solution under test through a suitable filter.

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 280 nm

Column: 4.6-mm × 15.0-cm; 5-µm packing L7

Flow rate: 1 mL/min

Injection volume: 20 µL

Run time: NLT 1.5 times the retention time of galantamine

System suitability

Sample: Standard solution

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: Standard solution and Sample solution

Calculate the concentration (Ci) of galantamine (C17H21NO3) in the sample withdrawn from the vessel at each time point (i):

\[ \text{Result}_i = C_i \times \frac{V_i}{L_i} \times 100 \]

\[ \text{Result}_2 = \left( \frac{C_i \times (V - V_i)}{L_i} \right) \times 100 \]

\[ \text{Result}_3 = \left( \frac{C_i \times (V - 2 \times V_i)}{L_i} \right) \times 100 \]

\[ \frac{C_i}{C_i} = \text{concentration of galantamine in the portion of sample withdrawn at time point } i \text{ (mg/mL)} \]

\[ V = \text{volume of Medium, 900 mL} \]

\[ L = \text{label claim (mg/Capsule)} \]

\[ V_i = \text{volume of the Sample solution withdrawn at each time point (mL)} \]

Tolerances: See Table 6.

Table 6

<table>
<thead>
<tr>
<th>Time Point (i)</th>
<th>Time (h)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>10-30</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>45-65</td>
</tr>
<tr>
<td>3</td>
<td>12</td>
<td>NLT 80</td>
</tr>
</tbody>
</table>

The percentage of the labeled amount of galantamine (C17H21NO3) dissolved at the times specified conforms to Dissolution (711), Acceptance Table 2.

• UNIFORMITY OF DOSAGE UNITS (905): Meet the requirements

IMPURITIES

Change to read:

• ORGANIC IMPURITIES

Solution A: *1.7 g/L of dibasic potassium phosphate* (BB 1-Jun-2016) and *3.0 g/L of monobasic potassium phosphate* (BB 1-Jun-2016) in water

Solution B: Acetonitrile

Mobile phase: See Table 7.

Table 7

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Solution A (%)</th>
<th>Solution B (%)</th>
<th>Flow Rate (mL/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>97</td>
<td>3</td>
<td>0.7</td>
</tr>
<tr>
<td>22</td>
<td>69</td>
<td>31</td>
<td>0.7</td>
</tr>
<tr>
<td>24</td>
<td>25</td>
<td>75</td>
<td>1.2</td>
</tr>
<tr>
<td>27</td>
<td>25</td>
<td>75</td>
<td>1.2</td>
</tr>
<tr>
<td>29</td>
<td>97</td>
<td>3</td>
<td>0.7</td>
</tr>
<tr>
<td>35</td>
<td>97</td>
<td>3</td>
<td>0.7</td>
</tr>
</tbody>
</table>

Diluent: Methanol and Solution A (60:40)

System suitability solution: 0.31 mg/mL of USP Galantamine Hydrobromide Related Compounds Mixture RS in Diluent

©2016 The United States Pharmacopeial Convention All Rights Reserved.
**Standard solution:** 0.0015 mg/mL of USP Galantamine Hydrobromide RS (equivalent to 0.0012 mg/mL of galantamine) in Diluent

**Sample solution:** Nominal 0.24 mg/mL of galantamine from NLT 20 Capsules prepared as follows. Transfer a suitable portion of the contents from NLT 20 Capsules to a suitable volumetric flask, and dilute with Diluent to volume. Sonication and shaking may be used to promote dissolution. Allow the solution to sit for NLT 24 h, and then clarify the solution using a suitable filter of 0.45-µm pore size.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

**Mode:** LC

**Detector:** UV 230 nm

**Column:** 3.0-mm × 15.0-cm; 5-µm packing L1

**Column temperature:** 35°C

**Flow rate:** See Table 7.

**Injection volume:** 10 µL

**System suitability**

**Samples:** System suitability solution and Standard solution

[NOTE—See Table 8 for relative retention times.]

**Suitability requirements**

**Resolution:** NLT 3.4 between galantamine and 6S-galantamine (also known as 6α-hexahydrogalantamine), System suitability solution

**Relative standard deviation:** NMT 5.0%, Standard solution

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of each degradation product in the portion of Capsules taken:

\[ \text{Result} = \left( \frac{r_1}{r_3} \right) \times \left( \frac{C_2}{C_0} \right) \times \left( \frac{M_1}{M_2} \right) \times 100 \]

- \( r_1 \) = peak response of each degradation product from the Sample solution
- \( r_3 \) = peak response of galantamine from the Standard solution
- \( C_1 \) = concentration of USP Galantamine Hydrobromide RS in the Standard solution (mg/mL)
- \( C_0 \) = nominal concentration of galantamine in the Sample solution (mg/mL)
- \( M_1 \) = molecular weight of galantamine, 287.35
- \( M_2 \) = molecular weight of galantamine hydride, 368.27

**Acceptance criteria:** See Table 8. Disregard peaks less than 0.05%.

### Table 8

<table>
<thead>
<tr>
<th>Name</th>
<th>Relative Retention Time</th>
<th>Acceptance Criteria, NMT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Desmethyl galantamine</td>
<td>0.57</td>
<td>0.5</td>
</tr>
<tr>
<td>Galantamine N-oxide</td>
<td>0.75</td>
<td>0.5</td>
</tr>
<tr>
<td>Dihydropalantamine</td>
<td>0.87</td>
<td>—</td>
</tr>
<tr>
<td>Galantamine</td>
<td>1.0</td>
<td>—</td>
</tr>
<tr>
<td>6S-Galantamine</td>
<td>1.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Didehydroxygalantamine</td>
<td>1.9</td>
<td>—</td>
</tr>
<tr>
<td>Any unspecified degradation product</td>
<td>—</td>
<td>0.2</td>
</tr>
<tr>
<td>Total degradation products</td>
<td>—</td>
<td>1.2</td>
</tr>
</tbody>
</table>

* (4α,5,6R,8aR)-4α,5,9,10,11,12-Hexahydro-3-methoxy-6H-benzofuro[3a,3,2-f][2]benzazepin-6-ol.

† This degradation product may be found if the drug substance is isolated from a natural source.

‡ (4α,5,6R,8aR)-4α,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-f][2]benzazepin-6-ol, N-oxide; also known as 6b-Hexahydropalantamine.

§ (4α,5,6R,8aR)-4α,5,7,8,9,10,11,12-Octahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, also known as 6a-Octahydrolalantamine.

® This is a process impurity and is listed for information only. It is controlled in the drug substance. It is not to be reported and is not to be included in the total degradation products.

° (4α,5,6R,8aR)-9,10,11,12-Tetrahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzepine; also known as Tetrahydropalantamine.

### ADDITIONAL REQUIREMENTS

**Packaging and Storage:** Preserve in tight, light-resistant containers, and store at controlled room temperature.

**Labeling:** When more than one Dissolution test is given, the labeling states the Dissolution test used only if Test 1 is not used.

**USP Reference Standards (11)**

USP Galantamine Hydrobromide RS

USP Galantamine Hydrobromide Related Compounds Mixture RS

Galantamine hydrobromide; 6b-Hexahydropalantamine (galantamine N-oxide); (4α,5,6R,8aR)-4α,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, N-oxide.

C₁₇H₁₉NO₃ 303.35

6b-Hexahydropalantamine (dihydrogalantamine); (4α,5,6R,8aR)-4α,5,7,8,9,10,11,12-Octahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol.

C₁₇H₂₁NO₃ 287.35

6a-Hexahydropalantamine (6S-galantamine); (4α,5,6S,8aS)-4α,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol.

C₁₇H₂₁NO₃ 289.37

6S-Galantamine or epigalantamine; (4α,5,6S,8aS)-4α,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepine; also known as 6a-Hexahydropalantamine.

C₁₇H₂₃NO₃ 291.39

**Tetrahydropalantamine (didehydroxygalantamine); (4α,5,8aS)-9,10,11,12-Tetrahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzepine.

C₁₇H₁₉NO₃ 269.34

©2016 The United States Pharmacopeial Convention All Rights Reserved.